<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="36064">Taxanes</z:chebi> are microtubule-stabilizing agents that have anticancer activity against several types of human <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Although the primary mechanism of action of these drugs is well understood, the signaling pathways that confer resistance to these agents in certain types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> remain poorly understood </plain></SENT>
<SENT sid="2" pm="."><plain>In particular, the association of p53 with the mechanism(s) of <z:chebi fb="0" ids="36064">taxane</z:chebi>-mediated cell <z:hpo ids='HP_0011420'>death</z:hpo> is still controversial </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we showed that p53 has a profound inhibitory effect on docetaxel (Doc)-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in prostate and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells and that caspases play a critical role in this process </plain></SENT>
<SENT sid="4" pm="."><plain>Doc induced <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> at high levels in p53-null PC3 cells, at intermediate levels in p53-mutant DU145 cells and at low levels in p53 <z:mp ids='MP_0002169'>wild-type</z:mp> LNCaP cells </plain></SENT>
<SENT sid="5" pm="."><plain>While transient overexpression of p53 in PC3 cells suppressed Doc-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, knockdown of p53 in LNCaP cells <z:mp ids='MP_0006042'>increased apoptosis</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>This finding was further confirmed using an isogenic pair of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines, HCT-116 p53-/- and p53+/+, indicating that p53 inhibits induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> by Doc </plain></SENT>
<SENT sid="7" pm="."><plain>To our knowledge, this is the first report describing that chemical or genetic knockout of p53 enhances the susceptibility of both prostate and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells to Doc-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>These results may suggest an approach to stratify patients for regimens involving Doc </plain></SENT>
</text></document>